Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

Trial Profile

Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

Completed
Phase of Trial: Phase II/III

Latest Information Update: 26 Aug 2016

At a glance

  • Drugs Susoctocog alfa (Primary)
  • Indications Haemophilia A
  • Focus Registrational; Therapeutic Use
  • Sponsors Baxter Healthcare Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Nov 2015 Results published in a Baxalta media release.
    • 13 Nov 2015 The European Commission granted marketing authorization for Obizur in November 2015, according to a Baxalta media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top